[ad_1] Immunotherapy with pembrolizumab improves survival in patients with recurrent or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at ESMO 2018 Congress in Munich. The current standard treatment for …
Read More »Metastatic cancer screening gets a computational upgrade
[ad_1] Tracing and predicting the course that metastatic cancers take through the body can shed light on the cellular changes that lead to metastasis. Metastatic disease causes about 90 percent of cancer …
Read More »